Barclays’s Neurogene NGNE Stock Holding History

Barclays’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-60	Closed	-$3K	–	7296
2018 Q2	$3K	Buy	+60	New	+$15.6K	﹤0.01%	6785

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Barclays's NGNE Position: Q2 2026 in Review

Barclays increased its Neurogene (NGNE) stake by 20% in Q2 2026, buying an estimated $15.4K and bringing the position to 3,310 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4024.

Barclays first reported a position in NGNE in Q4 2015 and has held it in 27 quarters since. The position peaked at $861K in Q1 2022. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

Barclays held 3,310 shares of Neurogene worth $104K as of Q2 2026.
Barclays bought 559 Neurogene shares in Q2 2026, an estimated $15.4K.
Neurogene made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4024 holding.
Barclays first reported a position in Neurogene in Q4 2015 and has held it in 27 quarters since.
Barclays's Neurogene position peaked at $861K in Q1 2022.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.